Extendicare (TSE:EXE) had its price target upped by stock analysts at National Bank Financial to C$8.50 in a report issued on Monday, Stock Target Advisor reports. The brokerage presently has a “na” rating on the stock. National Bank Financial’s target price would suggest a potential upside of 5.99% from the stock’s previous close.
Several other research analysts have also commented on EXE. TD Securities boosted their price objective on shares of Extendicare from C$7.00 to C$8.00 and gave the stock a “hold” rating in a research note on Friday. National Bankshares boosted their price objective on shares of Extendicare from C$8.00 to C$8.50 in a research note on Monday. Finally, Leede Jones Gab reissued a “buy” rating on shares of Extendicare in a research report on Monday, March 1st. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Extendicare presently has an average rating of “Hold” and a consensus price target of C$7.32.
Shares of TSE EXE traded down C$0.07 during trading hours on Monday, hitting C$8.02. 166,179 shares of the stock were exchanged, compared to its average volume of 292,968. The company has a quick ratio of 0.93, a current ratio of 1.06 and a debt-to-equity ratio of 442.45. The company has a market cap of C$718.29 million and a PE ratio of 13.39. The firm has a fifty day moving average price of C$7.75 and a 200-day moving average price of C$6.77. Extendicare has a 12 month low of C$5.06 and a 12 month high of C$8.13.
Extendicare Company Profile
Extendicare Inc, through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; retirement living services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as contract and consulting services to third parties.
Recommended Story: What is a price target?
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.